Purpose : To identify predictive factors for deterioration of lower urinary tract symptoms (LUTS) after iodine-125 (125I) brachytherapy for prostate cancer. Materials and Methods : 42 patients with localized prostate cancer treated with 125I brachytherapy as monotherapy between January 2013 and October 2014 were reviewed. In all patients, the prescribed dose was 160 Gy. Patients were asked to complete the International Prostate Symptom Score (IPSS) questionnaire just before and 3 months after the treatment. With an increase in IPSS ≥ 12 points defined as indicating obvious deterioration of LUTS (ODL), we analyzed the association between ODL and the following factors : age ; total activity of the sources ; prostate volume ; and dose-volume histogram (DVH) parameters, including V150 (%) of the prostate, V150 (cc) of the prostate, and D30 (Gy) of the urethra (minimal dose received by 30% of the urethral volume). Results : Seventeen (40.5%) patients developed ODL. On univariate analyses, V150 (%) and V150 (cc) were found to be significantly associated with ODL. On multivariate analysis, only V150 (cc) was shown to have a significant
relationship with ODL (P＝0.039). Conclusion : V150 (cc) could be a predictive factor for deterioration of LUTS after 125I brachytherapy in prostate cancer patients.
Objective : Although calcium phosphate cement (CPC) is a bone substitute material having good formativeness, biocompatibility, and osteoconductivity, it has very slow biodegradability in vivo. This study aimed to create a
new porous bone cement with enough strength, good formativeness, biodegradation, and osteoconductivity for bone regeneration by adding porous β-tricalcium phosphate (β-TCP) granules to CPC. Methods : A commercially available CPC and porous β-TCP were used in this study. Three testing materials with different mixing ratios of CPC and β-TCP (C0, C30 and C50, having mixing ratios of β-TCP of 0, 30, and 50 wt%, respectively) were examined. We evaluated the basic materialological properties in vitro. In addition, biodegradation and osteoconductivity were evaluated in vivo by implantation in rabbit femurs. Results : The setting times for C30 (15 minutes) and C50 (18 minutes) were thought to be within a clinically
acceptable range. Although the compressive strength decreased with increasing content of β-TCP, that of C50 was the same as for cancellous bone. The porosity and permeability increased with addition of more β-TCP granules. Histological evaluation revealed that biodegradability of the material increased with the addition of more β-TCP granules and the material had good bioactivity. Notably, at 36 weeks after implantation, C50 was almost completely resorbed and replaced by regenerated bone. Conclusions : The results of this study suggested that the composite created by adding equal weight percent of porous β-TCP granules to CPC paste had good biodegradability and adequate mechanical strength, and was adaptable as a bone substitute for bone defect repairs.
A pancreatic mass was found in a 47-year-old female by abdominal CT. 18F-fluorodeoxyglucose positron emission tomography (FDG PET) showed abnormal uptake in the pancreatic mass as well as in the bilateral hilar region of the chest. Chest CT revealed the presence of bilateral hilar lymphadenopathy (BHL). These findings suggested not only pancreatic carcinoma but also autoimmune pancreatitis (AIP). A pancreatoduodenectomy was performed and the pancreatic lesion was diagnosed as pancreatic carcinoma. Non-caseous granulomas were observed in the peri-pancreatic tissue and regional lymph nodes of the pancreas, and they were thought to be sarcoid-like reactions. Hilar 18F-FDG uptake had vanished on the follow-up PET study ; therefore the result suggested that BHL was also a sarcoid-like reaction. Lymphadenopathy due to sarcoid-like reaction associated with malignancy should be considered in the differentiation between a pancreatic carcinoma and AIP.